source
- STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and moreNovartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deathsSTAT · 9h ago↗ source
- Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 23h ago↗ source
- Asia-Pacific Roundup: India proposes immediate license suspensions for manufacturers of substandard drugsThe Indian government has proposed immediately suspending the license of any company that produces a drug that is not of standard quality.